Lipid nanoparticles for hepatic delivery of small interfering RNA

Biomaterials

Volumn 33, Issue 25, 2012, Pages 5924-5934

  Yu, Bo ^a,b   Hsu, Shu Hao ^b   Zhou, Chenguang ^b   Wang, Xinmei ^b   Terp, Megan C ^a,b   Wu, Yun ^b   Teng, Lesheng ^b,c   Mao, Yicheng ^b   Wang, Feng ^b   Xue, Weiming ^a   Jacob, Samson T ^b,d   Ghoshal, Kalpana ^b,d   Lee, Robert J ^b,d   Lee, Ly J ^a,b,d  

^a Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c JILIN UNIVERSITY   (China)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Cationic lipids; Hepatocellular carcinoma; Lipid nanoparticles; Small interfering RNA

Indexed keywords

CATIONIC LIPIDS; CLINICAL APPLICATION; CYTOSOLS; GENE SILENCING; HEPATOCELLULAR CARCINOMA; IN-VIVO; LINOLENIC ACIDS; LIPID NANOPARTICLES; LIPOFECTAMINE; LIVER DISEASE; SIRNA DELIVERY; SMALL INTERFERING RNA; SMALL INTERFERING RNA (SIRNA); TERTIARY AMINE; THERAPEUTIC APPLICATION; TRANSFECTION AGENTS;

GENES; LINOLEIC ACID; LIPIDS; LIPOSOMES; MOLECULAR BIOLOGY; NANOPARTICLES; POLYUNSATURATED FATTY ACIDS;

RNA;

CLATHRIN; LINOLEIC ACID; LINOLENIC ACID; LIPID NANOPARTICLE; LIPOFECTAMINE; NANOPARTICLE; OLEIC ACID; SMALL INTERFERING RNA; TERTIARY AMINE; TRIS(2 AMINOETHYL)AMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; ENDOCYTOSIS; GENE ACTIVITY; GENE SILENCING; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; IONIZATION; LIVER; LIVER CELL CARCINOMA; LIVER DISEASE; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PINOCYTOSIS; PRIORITY JOURNAL; RNA TRANSPORT; ZETA POTENTIAL;

ANIMALS; CELL LINE; COLLOIDS; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; ETHYLENEDIAMINES; FATTY ACIDS, UNSATURATED; HUMANS; LIPIDS; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED ICR; NANOPARTICLES; RNA STABILITY; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

MUS;

EID: 84862163934     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.002     Document Type: Article

References (34)

1. Arbuthnot P., Thompson L.J. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol 2008, 14:1670-1681.
2. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007, 59:75-86.
3. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
4. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucl Acids Res 2008, 36:4158-4171.
5. Love K.T., Mahon K.P., Levins C.G., Whitehead K.A., Querbes W., Dorkin J.R., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A 2010, 107:1864-1869.
6. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11:59-67.
7. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
8. Li L.J., Wang H.Y., Ong Z.Y., Xu K.J., Ee P.L.R., Zheng S.S., et al. Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today 2010, 5:296-312.
9. Rozema D.B., Lewis D.L., Wakefield D.H., Wong S.C., Klein J.J., Roesch P.L., et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007, 104:12982-12987.
10. Schroeder A., Levins C.G., Cortez C., Langer R., Anderson D.G. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010, 267:9-21.
11. Stanton M.G., Colletti S.L. Medicinal chemistry of siRNA delivery. J Med Chem 2010, 53:7887-7901.
12. Wu S.Y., McMillan N.A. Lipidic systems for in vivo siRNA delivery. AAPS J 2009, 11:639-652.
13. Yu B., Zhao X., Lee L.J., Lee R.J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J 2009, 11:195-203.
14. Adami R.C., Seth S., Harvie P., Johns R., Fam R., Fosnaugh K., et al. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther 2011, 19:1141-1151.
15. Lin X., Li L., Wang R., Wilcox D., Zhao X., Song J., et al. A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA 2011, 17:603-612.
16. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569.
17. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119:661-673.
18. Podesta J.E., Kostarelos K. Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery. Methods Enzymol 2009, 464:343-354.
19. Chen Y., Bathula S.R., Yang Q., Huang L. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol 2010, 130:2790-2798.
20. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010, 18:1650-1656.
21. Heyes J., Palmer L., Bremner K., MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005, 107:276-287.
22. Yang X., Koh C.G., Liu S., Pan X., Santhanam R., Yu B., et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm 2009, 6:221-230.
23. Kaneda M.M., Sasaki Y., Lanza G.M., Milbrandt J., Wickline S.A. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 2010, 31:3079-3086.
24. Zhang Y., Zhou C., Kwang K.J., Wang X., Yung B., Lee L.J., et al. Efficient siRNA delivery using a polyamidoamine dendrimer with a modified pentaerythritol core. Pharm Res 2012, 29:11-20.
25. Geusens B., Lambert J., De Smedt S.C., Buyens K., Sanders N.N., Van Gele M. Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J Control Release 2009, 133:214-220.
26. Weisman S., Hirsch-Lerner D., Barenholz Y., Talmon Y. Nanostructure of cationic lipid-oligonucleotide complexes. Biophys J 2004, 87:609-614.
27. Zhou C., Mao Y., Sugimoto Y., Zhang Y., Kanthamnen N., Yu B., et al. SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm 2012, 9:201-210.
28. Akinc A., Goldberg M., Qin J., Dorkin J.R., Gamba-Vitalo C., Maier M., et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009, 17:872-879.
29. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010, 18:1357-1364.
30. Lafleur M., Bloom M., Cullis P.R. Lipid polymorphism and hydrocarbon order. Biochem Cell Biol 1990, 68:1-8.
31. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
32. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
33. Peng X.H., Cao Z.H., Xia J.T., Carlson G.W., Lewis M.M., Wood W.C., et al. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res 2005, 65:1909-1917.
34. Huang L., Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011, 13:507-530.